Together, these data show that FGF1 signaling involves ER activation in endocrine-resistant obesity-associated breast cancers, and that one consequence may be metabolic reprogramming toward an aggressive glycolytic tumor phenotype. The gene discussed is FGF1; the disease is neoplasm.